Ancillary analyses
tumor, helper T-inducer, Tumor
CANCER, TUMOR, TUMOR
Ancillary studies will be conducted to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine with anti-PDL1 therapy (atezolizumab) and bevacizumab in unresectable HCC, and to decipher the molecular parameters determining the clinical outcomes. Biomarkers correlated with combined immunotherapy efficacy will be determined.Biomonitoring will be performed at baseline, at M2 and M6. A total of 50 ml of blood will be collected at each biomonitoring time point: six EDTA 6 ml tubes for PBMC collection, one EDTA 6 ml tube for plasma collection, and two EDTA 4 ml tube for plasma for ctDNA collection.Tumor samples collection:Tumor samples obtained by biopsies or surgery at diagnosis will be centralized for translational research program, to measure by immunohistochemistry immune-related biomarkers, tumor genotyping and RNA sequencing analyses.A fresh tumor biopsy will be performed at progression and in case of surgery or radiofrequency after tumor response (optional). These tumor samples will be collected for translational research: RNA sequencing (RNA from the biopsy will be isolated and stored at -80 °C) and Antigen-specific T cell monitoring.